vs
ANGIODYNAMICS INC（ANGO）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
REPUBLIC BANCORP INC的季度营收约是ANGIODYNAMICS INC的1.2倍（$94.3M vs $79.4M），REPUBLIC BANCORP INC净利率更高（24.2% vs -8.0%，领先32.2%），ANGIODYNAMICS INC同比增速更快（9.0% vs 5.3%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $4.2M），过去两年ANGIODYNAMICS INC的营收复合增速更高（2.8% vs -11.5%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
ANGO vs RBCAA — 直观对比
营收规模更大
RBCAA
是对方的1.2倍
$79.4M
营收增速更快
ANGO
高出3.7%
5.3%
净利率更高
RBCAA
高出32.2%
-8.0%
自由现金流更多
RBCAA
多$156.9M
$4.2M
两年增速更快
ANGO
近两年复合增速
-11.5%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $94.3M |
| 净利润 | $-6.3M | $22.8M |
| 毛利率 | 56.4% | — |
| 营业利润率 | -7.7% | 29.3% |
| 净利率 | -8.0% | 24.2% |
| 营收同比 | 9.0% | 5.3% |
| 净利润同比 | 40.9% | 20.0% |
| 每股收益（稀释后） | $-0.15 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGORBCAA
| Q4 25 | $79.4M | $94.3M | ||
| Q3 25 | $75.7M | $93.5M | ||
| Q2 25 | $80.2M | $93.8M | ||
| Q1 25 | $72.0M | $135.8M | ||
| Q4 24 | $72.8M | $89.5M | ||
| Q3 24 | $67.5M | $88.1M | ||
| Q2 24 | $71.0M | $86.9M | ||
| Q1 24 | $75.2M | $120.3M |
净利润ANGORBCAA
| Q4 25 | $-6.3M | $22.8M | ||
| Q3 25 | $-10.9M | $29.7M | ||
| Q2 25 | $-6.0M | $31.5M | ||
| Q1 25 | $-4.4M | $47.3M | ||
| Q4 24 | $-10.7M | $19.0M | ||
| Q3 24 | $-12.8M | $26.5M | ||
| Q2 24 | $-13.4M | $25.2M | ||
| Q1 24 | $-187.7M | $30.6M |
毛利率ANGORBCAA
| Q4 25 | 56.4% | — | ||
| Q3 25 | 55.3% | — | ||
| Q2 25 | 52.7% | — | ||
| Q1 25 | 54.0% | — | ||
| Q4 24 | 54.8% | — | ||
| Q3 24 | 54.4% | — | ||
| Q2 24 | 54.3% | — | ||
| Q1 24 | 47.7% | — |
营业利润率ANGORBCAA
| Q4 25 | -7.7% | 29.3% | ||
| Q3 25 | -14.1% | 40.4% | ||
| Q2 25 | -7.2% | 43.0% | ||
| Q1 25 | -13.9% | 44.1% | ||
| Q4 24 | -15.2% | 25.8% | ||
| Q3 24 | -19.4% | 38.4% | ||
| Q2 24 | -20.4% | 37.0% | ||
| Q1 24 | -265.9% | 32.2% |
净利率ANGORBCAA
| Q4 25 | -8.0% | 24.2% | ||
| Q3 25 | -14.4% | 31.8% | ||
| Q2 25 | -7.5% | 33.5% | ||
| Q1 25 | -6.1% | 34.8% | ||
| Q4 24 | -14.7% | 21.2% | ||
| Q3 24 | -19.0% | 30.1% | ||
| Q2 24 | -18.9% | 29.0% | ||
| Q1 24 | -249.7% | 25.4% |
每股收益（稀释后）ANGORBCAA
| Q4 25 | $-0.15 | — | ||
| Q3 25 | $-0.26 | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $-0.11 | — | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.35 | — | ||
| Q1 24 | $-4.67 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $220.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $176.3M | $1.1B |
| 总资产 | $269.7M | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANGORBCAA
| Q4 25 | $41.6M | $220.0M | ||
| Q3 25 | $38.8M | $484.2M | ||
| Q2 25 | $55.9M | $484.8M | ||
| Q1 25 | $44.8M | $793.0M | ||
| Q4 24 | $54.1M | $432.2M | ||
| Q3 24 | $55.0M | $530.9M | ||
| Q2 24 | $76.1M | $400.1M | ||
| Q1 24 | $78.5M | $546.4M |
总债务ANGORBCAA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益ANGORBCAA
| Q4 25 | $176.3M | $1.1B | ||
| Q3 25 | $178.9M | $1.1B | ||
| Q2 25 | $183.0M | $1.1B | ||
| Q1 25 | $185.9M | $1.0B | ||
| Q4 24 | $186.8M | $992.0M | ||
| Q3 24 | $196.6M | $979.7M | ||
| Q2 24 | $205.6M | $955.4M | ||
| Q1 24 | $218.7M | $935.6M |
总资产ANGORBCAA
| Q4 25 | $269.7M | $7.0B | ||
| Q3 25 | $265.6M | $7.0B | ||
| Q2 25 | $280.1M | $7.0B | ||
| Q1 25 | $285.4M | $7.1B | ||
| Q4 24 | $291.6M | $6.8B | ||
| Q3 24 | $293.6M | $6.7B | ||
| Q2 24 | $317.7M | $6.6B | ||
| Q1 24 | $324.8M | $6.9B |
负债/权益比ANGORBCAA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $161.1M |
| 自由现金流率自由现金流/营收 | 5.3% | 170.9% |
| 资本支出强度资本支出/营收 | 0.5% | 7.5% |
| 现金转化率经营现金流/净利润 | — | 7.37× |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $288.6M |
8季度趋势，按日历期对齐
经营现金流ANGORBCAA
| Q4 25 | $4.7M | $168.2M | ||
| Q3 25 | $-15.9M | $33.3M | ||
| Q2 25 | $18.8M | $8.4M | ||
| Q1 25 | $-13.2M | $93.2M | ||
| Q4 24 | $2.5M | $149.0M | ||
| Q3 24 | $-18.3M | $51.3M | ||
| Q2 24 | $5.0M | $4.0M | ||
| Q1 24 | $-12.5M | $71.2M |
自由现金流ANGORBCAA
| Q4 25 | $4.2M | $161.1M | ||
| Q3 25 | $-16.6M | $30.8M | ||
| Q2 25 | $18.0M | $5.2M | ||
| Q1 25 | $-15.0M | $91.6M | ||
| Q4 24 | $1.7M | $143.2M | ||
| Q3 24 | $-19.3M | $49.8M | ||
| Q2 24 | $4.4M | $2.7M | ||
| Q1 24 | $-13.1M | $69.1M |
自由现金流率ANGORBCAA
| Q4 25 | 5.3% | 170.9% | ||
| Q3 25 | -22.0% | 32.9% | ||
| Q2 25 | 22.5% | 5.5% | ||
| Q1 25 | -20.8% | 67.4% | ||
| Q4 24 | 2.3% | 160.0% | ||
| Q3 24 | -28.7% | 56.5% | ||
| Q2 24 | 6.2% | 3.1% | ||
| Q1 24 | -17.5% | 57.5% |
资本支出强度ANGORBCAA
| Q4 25 | 0.5% | 7.5% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 1.0% | 3.5% | ||
| Q1 25 | 2.5% | 1.2% | ||
| Q4 24 | 1.1% | 6.5% | ||
| Q3 24 | 1.6% | 1.7% | ||
| Q2 24 | 0.8% | 1.5% | ||
| Q1 24 | 0.8% | 1.7% |
现金转化率ANGORBCAA
| Q4 25 | — | 7.37× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 1.93× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
RBCAA
暂无分部数据
